[Market Highlight] Orym Therapeutics Hits Record High on KRW 145 Billion CPS Investment
Orym Therapeutics is showing strong performance in early trading.
As of 9:05 a.m. on December 19, Orym Therapeutics was trading at 97,300 won, up 11.45% (10,000 won) from the previous day. During the session, the price rose to 98,600 won, setting a new 52-week high. The news that the company secured a convertible preferred stock (CPS) investment worth 145 billion won appears to have boosted investor sentiment.
This CPS investment round, which included existing investor KB Investment as well as several new investors such as Wise Asset Management and Korea Investment Partners, was pursued to further develop existing pipelines like ORM-1153, develop new payload classes, and advance the DAC platform.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Seungjoo, CEO of Orym Therapeutics, stated, "This investment will provide a crucial foundation for advancing our key pipelines that are about to enter the clinical stage, developing new payloads, and establishing a platform capable of creating differentiated new drug candidates in a variety of disease areas beyond oncology."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.